Recombinant SARS-CoV-2 Assay for Omicron Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid spread of the Omicron SARS-CoV-2 variant has highlighted the need for effective methods to assess cross-neutralization capabilities, as previous infections or vaccinations show reduced neutralization titers against Omicron, indicating a decrease in immune protection.
Innovation Solution
A high-throughput neutralization assay is developed by engineering the Omicron spike gene into a recombinant mNeonGreen USA-WA1/2020 SARS-CoV-2, allowing for the measurement of neutralization titers in patient sera, using a fluorescent focus reduction neutralization test (FFRNT) to evaluate cross-protection against Omicron.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a neutralization assay is developed to measure cross-neutralization against Omicron, then the ability to assess immune protection is improved, but the complexity of the assay system increases
Solution Approach 1:
The patent uses a recombinant SARS-CoV-2 virus as an intermediary tool that expresses the Omicron spike protein on its surface. This recombinant virus serves as a mediator between the test antibodies and the Omicron virus, allowing neutralization assessment without requiring direct interaction with the actual Omicron virus. The recombinant virus carries a reporter protein (such as mNeonGreen or nanoluciferase) that enables detection of neutralization through fluorescence or luminescence signals, simplifying the measurement process while maintaining accuracy.
Solution Approach 2:
The patent employs fluorescent and luminescent reporter proteins (such as mNeonGreen, eGFP, or nanoluciferase) that produce detectable color or light signals when expressed in the recombinant virus. These color changes provide a quantitative readout for neutralization activity, allowing researchers to measure cross-neutralization capabilities through simple fluorescence or luminescence assays rather than complex viral plaque reduction methods.
2Reliability
If the Omicron spike gene is engineered into a recombinant virus for neutralization testing, then the assessment of cross-protection is improved, but the viral replication and detection requirements increase
Solution Approach 1:
The patent extracts and isolates the Omicron spike protein coding sequence from the full viral genome and places it into a recombinant SARS-CoV-2 virus backbone. This extracted spike protein gene is expressed on the surface of the recombinant virus, which then serves as a stable platform for neutralization testing. By separating the spike protein expression from the full viral replication cycle, the system maintains reliability in assessing cross-protection while reducing the complexity of viral replication and detection requirements.
Solution Approach 2:
The recombinant SARS-CoV-2 virus serves multiple functions simultaneously: it expresses the Omicron spike protein for neutralization testing, provides a controlled viral replication system for producing test virus particles, and incorporates reporter proteins for detection. This multi-functional design allows the same viral system to be used for vaccine efficacy testing, therapeutic antibody evaluation, and surveillance studies, reducing the need for multiple specialized assays.
3Measurement precision
If patient sera are tested for neutralization titers against Omicron, then the evaluation of immune protection is improved, but the time required for assay development and implementation increases
Solution Approach 1:
The patent performs preliminary actions by pre-engineering the recombinant virus with the Omicron spike protein and reporter genes before actual neutralization testing begins. The virus is pre-characterized for its replication properties and viral titer, and the assay protocol is pre-optimized for detecting neutralization activity. This preliminary preparation allows rapid implementation of cross-neutralization studies against Omicron sublineages without requiring time-consuming virus preparation and assay development during the actual testing phase.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay demonstrates low cross-neutralization against Omicron from previous non-Omicron infections, supporting the necessity for vaccination of formerly infected individuals to mitigate the health impact of the Omicron surge, and facilitates antiviral testing and therapeutic development.
Implementation Method 1
The reporter protein can be, for example but not limited to mNeonGreen (e.g., SEQ ID NO:4 and SEQ ID NO:5) or nanoluciferase reporter
Implementation Method 2
The reporter protein can be, for example but not limited to mNeonGreen (e.g., SEQ ID NO:4 and SEQ ID NO:5) or nanoluciferase reporter (e.g., SEQ ID NO:6 and SEQ ID NO:7)
Data Source
AI summary
Certain embodiments of the invention include recombinant reverse genetic systems for Omicron variant of SARS-CoV-2 virus.